PharmaGraphX

Log in Get Started

Pembrolizumab

Keytruda, Keytruda Qlex

Monoclonal antibody

Standard

Half-life

26 days

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Clinical alerts

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Hepatotoxic

Monitor liver function

Mechanism of action

Monoclonal antibody blocking PD-1 receptor, restoring anti-tumor T cell activity

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Lung Cancer, Non-squamous, Non-small Cell
·Kidney Cancer
·Invasive Breast Carcinoma
·Stage 0 Breast Cancer AJCC v6 and v7
·Stage I Breast Cancer AJCC v7

Interactions

No curated interaction pairs are recorded for Pembrolizumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Fatigue
Pruritus
Rash
Diarrhea
Immune-mediated adverse events

Pharmacokinetics

Published parameters · PMID:28493782

Half-life: 26 days
Protein binding: N/A
Clearance: 0.009 L/h; adult oncology patients (various solid tumors)
Volume of distribution: 6 L
Renally eliminated: 0%
Model: 1-compartment

Pregnancy & lactation

Not recorded for Pembrolizumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement